BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
- Thursday, November 10, 2022, 7:17
- Environment
- Add a comment
– PDUFA target action date set for September 9, 2023 – NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance – Company advancing preparations for robust commercial launch TEL AVIV, Israel, Nov. 10,…
About the Author
adminasapcorp has written 41802 stories on this site.